Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-man phase 1 trial of ERY-MET

Next Previous
Search
Trial Profile

First-in-man phase 1 trial of ERY-MET

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ERY-MET (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 11 Mar 2019 According to the ERYtech Pharma media release, The company has completed non-clinical studies in 2018 and activities in supoort of initiating this study are ongoing. The company expects to begin this trial in Europe in the first quarter of 2020.
    • 24 Jun 2018 According to an ERYtech Pharma media release, this study is expected to start in 2018, , with enrollment expected to commence in the first half of 2019.
    • 01 Apr 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top